Genitourinary Cancers

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

Claud M. Grigg Jr, MD, medical oncologist, Levine Cancer Institute-Ballantyne, Atrium Health, discusses sequencing challenges in renal cell carcinoma (RCC).

The FDA has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Convincing data have made the case for the use of immunotherapy in the frontline for advanced renal cell carcinoma, ushering in a second revolution in slightly more than a decade.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses atezolizumab plus bevacizumab in patients with non–clear cell renal cell carcinoma.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses next steps for research in renal cell carcinoma (RCC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses promising targets and pathways in the treatment of patients with bladder cancer.

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Paul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses patient factors to take into consideration when deciding appropriate treatment for patients with advanced renal cell carcinoma.